{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:02:59Z","timestamp":1792605779358,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ccl.2021.04.010","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T22:13:20Z","timestamp":1625782400000},"page":"389-402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis"],"prefix":"10.1016","volume":"39","author":[{"given":"Steven","family":"Law","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10038","key":"10.1016\/j.ccl.2021.04.010_bib1","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.010_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.ccl.2021.04.010_bib3","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-Diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.ccl.2021.04.010_bib4","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore Julian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2021.04.010_bib5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2019.12.063","article-title":"Diagnostic delay in wild type transthyretin cardiac amyloidosis - a clinical challenge","volume":"304","author":"Ladefoged","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ccl.2021.04.010_bib6","doi-asserted-by":"crossref","unstructured":"Hester L, Gifkins D, Bellew K, et\u00a0al. Diagnostic delay and characterization of the clinical prodrome in al amyloidosis related cardiomyopathy among 1,173 patients diagnosed between 2001-2018. 2020;75(11 Supplement 1):900.","DOI":"10.1016\/S0735-1097(20)31527-8"},{"issue":"22","key":"10.1016\/j.ccl.2021.04.010_bib7","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1182\/blood.V128.22.4448.4448","article-title":"Improved survival in AL amyloidosis: a population-based study on 1,430 patients diagnosed in Sweden 1995-2013","volume":"128","author":"Weiss","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ccl.2021.04.010_bib8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.010_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.12286","article-title":"Systemic amyloidosis in England: an epidemiological study","volume":"161","author":"Pinney","year":"2013","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.ccl.2021.04.010_bib10","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.ccl.2021.04.010_bib11","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMc1917321","article-title":"Epidemiologic and survival trends in amyloidosis, 1987\u20132019","volume":"382","author":"Ravichandran","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.010_bib12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"key":"10.1016\/j.ccl.2021.04.010_bib13","unstructured":"Mirzoyev SA, Edwards WD, Mohammed SF, et\u00a0al. Abstract 17926: cardiac amyloid deposition is common in elderly patients with heart failure and preserved ejection fraction. 2010;122(suppl_21):A17926."},{"issue":"2","key":"10.1016\/j.ccl.2021.04.010_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000495455","article-title":"Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis","volume":"141","author":"Vaxman","year":"2019","journal-title":"Acta Haematol"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.010_bib15","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bjh.15955","article-title":"Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers","volume":"186","author":"Rezk","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ccl.2021.04.010_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.ccl.2021.04.010_bib17","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.010_bib18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/13506129.2018.1498782","article-title":"Seven factors predict a delayed diagnosis of cardiac amyloidosis","volume":"25","author":"Bishop","year":"2018","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.010_bib19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac amyloidosis","volume":"6","author":"Giancaterino","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"6","key":"10.1016\/j.ccl.2021.04.010_bib20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/msj.21352","article-title":"Amyloid neuropathies","volume":"79","author":"Shin","year":"2012","journal-title":"Mt Sinai J Med"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.010_bib21","doi-asserted-by":"crossref","first-page":"e000098","DOI":"10.1161\/JAHA.113.000098","article-title":"Senile systemic amyloidosis: clinical features at presentation and outcome","volume":"2","author":"Pinney","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.010_bib22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/anec.12018","article-title":"The findings of electrocardiography in patients with cardiac amyloidosis","volume":"18","author":"Cheng","year":"2013","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"7","key":"10.1016\/j.ccl.2021.04.010_bib23","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi","year":"2010","journal-title":"Nat Rev Cardiol"},{"issue":"9","key":"10.1016\/j.ccl.2021.04.010_bib24","doi-asserted-by":"crossref","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"19","key":"10.1016\/j.ccl.2021.04.010_bib25","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1161\/01.CIR.0000068313.67758.4F","article-title":"Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis","volume":"107","author":"Koyama","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.010_bib26","doi-asserted-by":"crossref","first-page":"e005588","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters","volume":"10","author":"Pagourelias","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.010_bib27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.010_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10741-014-9470-7","article-title":"Cardiovascular magnetic resonance for amyloidosis","volume":"20","author":"Fontana","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.010_bib29","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","article-title":"Cardiovascular magnetic resonance in cardiac amyloidosis","volume":"111","author":"Maceira Alicia","year":"2005","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.010_bib30","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jcmg.2012.11.013","article-title":"Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis","volume":"6","author":"Karamitsos","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1 Part 1","key":"10.1016\/j.ccl.2021.04.010_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcmg.2019.03.026","article-title":"Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis","volume":"13","author":"Baggiano","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"issue":"16","key":"10.1016\/j.ccl.2021.04.010_bib32","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","article-title":"Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis","volume":"132","author":"Fontana","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.010_bib33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/eurheartj\/ehu444","article-title":"T1 mapping and survival in systemic light-chain amyloidosis","volume":"36","author":"Banypersad","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.010_bib34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jcmg.2017.02.012","article-title":"CMR-verified regression of cardiac AL amyloid after chemotherapy","volume":"11","author":"Martinez-Naharro","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.010_bib35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.010_bib36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1001\/jamainternmed.2019.5284","article-title":"Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis","volume":"180","author":"Woolen","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.010_bib37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00003072-198103000-00003","article-title":"Bone scintigram in cardiac amyloidosis: a case report","volume":"6","author":"Ali","year":"1981","journal-title":"Clin Nucl Med"},{"issue":"Suppl 1","key":"10.1016\/j.ccl.2021.04.010_bib38","doi-asserted-by":"crossref","first-page":"O16","DOI":"10.1186\/1750-1172-10-S1-O16","article-title":"DPD Scintigraphy for diagnosis of amyloidosis in 1191 patients\u2013 a single centre experience","volume":"10","author":"Hutt","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.010_bib39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jcmg.2013.08.015","article-title":"CMR-based differentiation of AL and ATTR cardiac amyloidosis","volume":"7","author":"Dungu","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"issue":"suppl_1","key":"10.1016\/j.ccl.2021.04.010_bib40","article-title":"An ECG\/ECHO comparison between AL and ATTR cardiac amyloidosis at diagnosis","volume":"34","author":"Boldrini","year":"2013","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.ccl.2021.04.010_bib41","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","article-title":"Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis","volume":"41","author":"Chacko","year":"2020","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.010_bib42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.13156","article-title":"Guidelines on the diagnosis and investigation of AL amyloidosis","volume":"168","author":"Gillmore","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.010_bib43","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1373\/clinchem.2008.117143","article-title":"Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine","volume":"55","author":"Palladini","year":"2009","journal-title":"Clin Chem"},{"issue":"6","key":"10.1016\/j.ccl.2021.04.010_bib44","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2215\/CJN.02290508","article-title":"Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease","volume":"3","author":"Hutchison","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.ccl.2021.04.010_bib45","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1681\/ASN.2006050460","article-title":"Amyloidosis-associated kidney disease","volume":"17","author":"Dember","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.010_bib46","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood-2011-06-358507","article-title":"Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients","volume":"119","author":"Sch\u00f6nland","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.010_bib47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/cjp2.126","article-title":"The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis","volume":"5","author":"Rezk","year":"2019","journal-title":"J\u00a0Pathol Clin Res"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.010_bib48","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/ejh.13458","article-title":"The value of screening biopsies in light-chain (AL) and transthyretin (ATTR) amyloidosis","volume":"105","author":"Cohen","year":"2020","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.ccl.2021.04.010_bib49","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJM199008233230803","article-title":"Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component","volume":"323","author":"Hawkins","year":"1990","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ccl.2021.04.010_bib50","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.ccl.2021.04.010_bib51","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A\u00a0European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.ccl.2021.04.010_bib52","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A\u00a0new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ccl.2021.04.010_bib53","unstructured":"Law S, Petrie A, Chacko L, et\u00a0al. Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage."},{"issue":"6","key":"10.1016\/j.ccl.2021.04.010_bib54","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.kint.2017.05.004","article-title":"Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor","volume":"92","author":"Rezk","year":"2017","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.010_bib55","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.13155","article-title":"Guidelines on the management of AL amyloidosis","volume":"168","author":"Wechalekar","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.ccl.2021.04.010_bib56","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41408-018-0137-9","article-title":"Deferred autologous stem cell transplantation in systemic AL amyloidosis","volume":"8","author":"Manwani","year":"2018","journal-title":"Blood Cancer J"},{"issue":"21","key":"10.1016\/j.ccl.2021.04.010_bib57","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1182\/blood.V116.21.1364.1364","article-title":"Validation of the criteria of response to treatment in AL amyloidosis","volume":"116","author":"Palladini","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ccl.2021.04.010_bib58","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.ccl.2021.04.010_bib59","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.010_bib60","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1038\/bcj.2017.26","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis","volume":"7","author":"Wechalekar","year":"2017","journal-title":"Blood Cancer J"},{"issue":"21","key":"10.1016\/j.ccl.2021.04.010_bib61","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood.V120.21.3138.3138","article-title":"Doxycycline used as post transplant antibacterial prophylaxis improves survival in patients with light chain amyloidosis undergoing autologous stem cell transplantation","volume":"120","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.010_bib62","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","article-title":"Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death","volume":"5","author":"Kristen","year":"2008","journal-title":"Heart Rhythm"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.010_bib63","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ndt\/gfaa293","article-title":"Renal transplant outcomes in amyloidosis","volume":"36","author":"Law","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"36","key":"10.1016\/j.ccl.2021.04.010_bib64","doi-asserted-by":"crossref","first-page":"8654","DOI":"10.1021\/bi00151a036","article-title":"Partial denaturation of transthyretin is sufficient for amyloid fibril formation in\u00a0vitro","volume":"31","author":"Colon","year":"1992","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/j.ccl.2021.04.010_bib65","first-page":"2802","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J\u00a0Neurol"},{"issue":"24","key":"10.1016\/j.ccl.2021.04.010_bib66","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"issue":"Suppl_1","key":"10.1016\/j.ccl.2021.04.010_bib67","first-page":"A13123","article-title":"Abstract 13123: diflunisal is associated with improved mortality in patients with wild-type ATTR cardiac amyloidosis: the BU amyloidosis center experience","volume":"140","author":"Mints","year":"2019","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ccl.2021.04.010_bib68","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.cardfail.2019.11.024","article-title":"Stabilization of cardiac function with diflunisal in transthyretin (ATTR) cardiac amyloidosis","volume":"26","author":"Lohrmann","year":"2020","journal-title":"J\u00a0Card Fail"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.010_bib69","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.010_bib70","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ccl.2021.04.010_bib71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ccl.2021.04.010_bib72","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2021.04.010_bib73","doi-asserted-by":"crossref","unstructured":"Dasgupta NR, Benson M. Improved survival of patients with transthyretin amyloid cardiomyopathy with inotersen (TTR specific antisense oligonucleotide). 2019;73(9 Supplement 1):811.","DOI":"10.1016\/S0735-1097(19)31418-4"},{"issue":"9","key":"10.1016\/j.ccl.2021.04.010_bib74","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1212\/WNL.0b013e318248df18","article-title":"Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy","volume":"78","author":"Yamashita","year":"2012","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ccl.2021.04.010_bib75","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/lt.24058","article-title":"Liver transplantation in transthyretin amyloidosis: issues and challenges","volume":"21","author":"Carvalho","year":"2015","journal-title":"Liver Transpl"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.010_bib76","first-page":"241","article-title":"Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis","volume":"33","author":"Rezk","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.ccl.2021.04.010_bib77","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.2008060614","article-title":"Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis","volume":"20","author":"Gillmore","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10, Supplement","key":"10.1016\/j.ccl.2021.04.010_bib78","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.cardfail.2020.09.101","article-title":"The clinical spectrum of T60a variant hereditary transthyretin amyloidosis in Ireland","volume":"26","author":"Hewitt","year":"2020","journal-title":"J\u00a0Card Fail"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865121000333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865121000333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:54:39Z","timestamp":1760007279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865121000333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0733865121000333"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2021.04.010","relation":{},"ISSN":["0733-8651"],"issn-type":[{"value":"0733-8651","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Diagnosis and Treatment of Cardiac and Renal Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccl.2021.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}